SONN icon

Sonnet BioTherapeutics

13 hedge funds and large institutions have $151K invested in Sonnet BioTherapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 3 closing their positions.

Holders
13
Holders Change
-1
Holders Change %
-7.14%
% of All Funds
0.21%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
6
Reduced
4
Closed
3
Calls
Puts
Net Calls
Net Calls Change
Name Market Value Shares Shares
Change
Shares
Change %
Geode Capital Management
1
Geode Capital Management
Massachusetts
$33K 29,467 -22,503 -43%
Vanguard Group
2
Vanguard Group
Pennsylvania
$20.8K 18,057 -115,754 -87%
TSS
3
Two Sigma Securities
New York
$20.7K 18,003 +6,018 +50%
HF
4
HRT Financial
New York
$18K 15,930 +15,930 New
Mariner
5
Mariner
Kansas
$16K 13,533
BlackRock
6
BlackRock
New York
$15.1K 13,104 +1 +0%
TRCT
7
Tower Research Capital (TRC)
New York
$11K 9,324 +5,037 +117%
ASN
8
Advisory Services Network
Georgia
$10.7K 9,322 +9,322 New
UBS Group
9
UBS Group
Switzerland
$3.24K 2,815 +2,814 +281,400%
Morgan Stanley
10
Morgan Stanley
New York
$1.31K 1,141 +1,000 +709%
IA
11
IFP Advisors
Florida
$1K 142 -1,858 -93%
Wells Fargo
12
Wells Fargo
California
$58 50 +21 +72%
Bank of America
13
Bank of America
North Carolina
$2 2 -11 -85%
VF
14
Virtu Financial
New York
-26,914 Closed
FIA
15
FNY Investment Advisers
New York
-90 Closed
Royal Bank of Canada
16
Royal Bank of Canada
Ontario, Canada
-1 Closed
CFGS
17
Concourse Financial Group Securities
Alabama